3 completed. 3 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Completed 3 |
| Phase 2 | 1 | Completed 1 |
Follow Lymphocytic Leukemia: new trials by email Literature Review of Lymphocytic Leukemia trials Research Report on Lymphocytic Leukemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Duvelisib in Combination With BMS-986345 in Lymphoid Malignancy BMS-986345, Duvelisib - Non Hodgkin Lymphoma, Hodgkin Lymphoma | Phase 1 | Completed | H. Lee Moffitt Cancer Center and Research Institute | 14 | 2021-11-18 | 2025-12-04 |
| A Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib in Participants With Treatment-naive Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Ibrutinib - Lymphocytic Leukemia | Phase 1 | Completed | Janssen Pharmaceutical K.K. | 8 | 2015-07-03 | 2019-08-14 |
| Everolimus and Alemtuzumab in Treating Patients With Recurrent Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma alemtuzumab, everolimus - Lymphocytic Leukemia | Phase 1 / Phase 2 | Completed | Mayo Clinic | 28 | 2009-07-01 | 2017-09-26 |
Leukemia, Lymphoid (3) · Hematologic Neoplasms (1) · Hodgkin Disease (1) · Lymphoma, Non-Hodgkin (1) · Neoplasms, Plasma Cell (1)
Hematologic Diseases (3) · Hemic and Lymphatic Diseases (3) · Immune System Diseases (3) · Immunoproliferative Disorders (3) · Leukemia (3) · Lymphatic Diseases (3) · Lymphoproliferative Disorders (3) · Neoplasms (3) · Neoplasms by Histologic Type (3) · Lymphoma (1) · Neoplasms by Site (1)
Alemtuzumab (1) · Azacitidine (1) · Everolimus (1) · duvelisib (1) · ibrutinib (1)
H. Lee Moffitt Cancer Center and Research Institute (1) · Janssen Pharmaceutical K.K. (1) · Mayo Clinic (1)
United States (2) · Japan (1)
Clive S. Zent, M.D. (1) · Hayder Saeed, MD (1) · Jose F. Leis, M.D. (1)